ANN ARBOR – HandyLab announced Tuesday that it has expanded its collaborative partnership with Manchester, UK-based DxS by signing a broader licensing agreement for the DxS Scorpions amplification technology enhancing the company’s focus in the in-vitro diagnostics marketplace.
.
Scorpions is a homogeneous, closed-tube format for PCR analysis for which DxS owns the worldwide Intellectual Property. The technology provides an accurate, rapid and reliable fluorescence-based signal generation system with application rights in in-vitro diagnostics, genetic analysis, bio-threat detection and environmental utility.
HandyLab’s products are positioned to decentralize nucleic acid testing. DxS is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the health care industry to enable the delivery of safe and effective medicines. Working predominately in the field of cancer, DxS has a range of companion diagnostic and research kits that detect mutations in oncogenes.
a>>
